Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 21, 2017; 23(3): 533-539
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.533
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.533
Table 1 Clinical symptoms in the control and experimental groups before treatment n (%)
Indices (clinical symptoms) | Control group (n = 30) | Experimental group (n = 90) | t/χ2 | P value |
Stomach ache | 17 (56.67) | 50 (55.56) | 0.025 | 0.874 |
Time to defecation (-x ± s) | 8.50 ± 1.31 | 8.71 ± 1.40 | -0.723 | 0.471 |
Blood and pus | 10 (33.33) | 29 (32.22) | 0.028 | 0.867 |
Tenesmus | 13 (43.33) | 38 (42.22) | 0.025 | 0.874 |
Interleukin-8 (ng/L) | 25.83 ± 3.01 | 24.97 ± 2.98 | 1.366 | 0.175 |
Table 2 Clinical symptoms of patients in the two groups after treatment n (%)
Group | Stomach ache | Time to defecation (-x ± s ) | Blood and pus | Tenesmus |
Control group | ||||
Before treatment | 17 (56.67) | 8.50 ± 1.31 | 10 (33.33) | 13 (43.33) |
After treatment | 13 (43.33) | 2.91 ± 0.97 | 5 (16.67) | 7 (23.33) |
t/χ2 | 3.548 | 18.784 | 7.401 | 9.000 |
P value | 0.060 | 0.000 | 0.007 | 0.003 |
Experimental group | ||||
Before treatment | 50 (55.56) | 8.71 ± 1.40 | 29 (32.22) | 38 (42.22) |
After treatment | 8 (8.89)a | 1.12 ± 0.87a | 4 (4.44)a | 6 (6.67)a |
t/χ2 | 49.864 | 43.684 | 25.776 | 34.213 |
P value | 0.000 | 0.000 | 0.000 | 0.000 |
Table 3 Comparison of interleukin-8 expression levels between the control and experimental groups
Group | Different time points | Mean | F | P value | |||
Day 0 | Day 10 | Day 20 | Day 30 | ||||
Control group | 25.83 ± 3.01 | 25.23 ± 2.87 | 24.68 ± 2.99 | 24.34 ± 2.98 | 25.02 ± 2.95 | 2.191 | 0.060 |
Experimental group | 24.97 ± 2.98 | 22.20 ± 2.90 | 15.95 ± 2.62 | 8.81 ± 2.13 | 17.98 ± 2.54 | 9.715 | 0.000 |
Mean | 25.40 ± 2.95 | 23.72 ± 2.88 | 20.32 ± 2.71 | 16.58 ± 2.35 | 19.26 ± 2.52 | 6.114 | 0.008 |
t | 1.366 | 4.969 | 15.249 | 31.117 | 12.617 | (F = 5.491, P = 0.032)1 | (F = 2.981, P = 0.139)2 |
P value | 0.175 | 0.000 | 0.000 | 0.000 | 0.000 |
Table 4 Adverse reactions in the control and experimental groups after treatment
Group | Stomach discomfort | Liver and kidney dysfunction | Headache | Rashes | Vomiting | Neck pain | Incidence |
Control group | 5 | 1 | 3 | 2 | 2 | 0 | 43.33% |
Experimental group | 0 | 0 | 0 | 0 | 0 | 7 | 7.78% |
- Citation: Zhao HY, Yang GT, Sun NN, Kong Y, Liu YF. Efficacy and safety of stellate ganglion block in chronic ulcerative colitis. World J Gastroenterol 2017; 23(3): 533-539
- URL: https://www.wjgnet.com/1007-9327/full/v23/i3/533.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i3.533